Loading...
•
Jun 30
Capricor Q2 2025 Earnings Report
Capricor reported a higher net loss in Q2 2025 amid increased R&D and G&A expenses, with no revenue recognized during the quarter.
Key Takeaways
In Q2 2025, Capricor Therapeutics posted a net loss of $25.9M or $0.57 per share, driven by increased operating expenses and no reported revenue. Cash balance at the end of the quarter was $122.8M, expected to fund operations into Q4 2026.
No revenue was reported in Q2 2025, down from $4.0M in Q2 2024
Net loss was $25.9M, or $0.57 per share
Operating expenses rose to $27.7M due to higher R&D and G&A costs
Cash balance stood at $122.8M, expected to fund operations into Q4 2026
Capricor
Capricor
Forward Guidance
Capricor expects current cash resources to fund operations through Q4 2026, excluding potential milestone payments.
Positive Outlook
- Cash position supports operations into Q4 2026
- FDA cleared IND for StealthX™ exosome-based vaccine
- HOPE-3 Phase 3 trial completed 12-month treatment period
- All 483 FDA inspection observations resolved
- Orphan Drug Designation granted for Becker MD
Challenges Ahead
- Zero revenue recognized in Q2 2025
- Net loss more than doubled YoY
- Increased R&D and G&A expenses
- Pending CRL response delays potential approval
- HOPE-3 data still blinded and results pending